STOCK TITAN

GILD Form 144: Johanna Mercier Reports 28,000-Share Sale via Morgan Stanley

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Gilead Sciences insider notice for proposed Rule 144 sale. The filing reports a proposed sale of 28,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $3,318,924.65 and the company’s outstanding shares listed as 1,240,806,916. The filer shows recent acquisitions including a 25,000-share stock option exercise dated 08/15/2025, 2,394 performance shares (01/31/2024) and 606 restricted shares (12/10/2023). The form also lists multiple dispositions by Johanna Mercier in the past three months, with individual sales and gross proceeds disclosed for each trade.

Positive

  • Clear Rule 144 disclosure: filing specifies broker, share count and aggregate market value for the proposed sale
  • Detailed acquisition history: includes dates and types (stock option exercise, performance shares, restricted stock)
  • Recent sales documented: multiple dispositions in the past three months with gross proceeds listed

Negative

  • Insider liquidity event: proposed sale equals $3.32 million, which may be viewed negatively by some investors
  • Multiple recent disposals: repeated sales by the same holder over the past three months could raise investor scrutiny

Insights

TL;DR: Insider has filed to sell a meaningful block of shares, disclosed recent grants and multiple recent sales.

The notice transparently discloses a proposed sale of 28,000 shares valued at $3.32 million via Morgan Stanley Smith Barney and enumerates recent acquisitions including a same-day stock option exercise of 25,000 shares. For investors, this is a routine Rule 144 disclosure showing an insider liquidity event and prior incremental dispositions over the past three months. The filing contains concrete quantities, dates and gross proceeds for recent sales, enabling verification of insider selling activity without offering commentary on motives.

TL;DR: Filing meets Rule 144 disclosure requirements; shows ongoing insider sales and recent equity grants.

The document fulfills required disclosures by identifying the broker, share counts, acquisition methods and recent sales by the holder. Notably, the filer recorded recent equity compensation events (performance shares and restricted stock) along with a sizable option exercise. From a governance perspective, the record of multiple disposals in the prior three months plus a new proposed sale warrants attention to insider selling patterns, but the filing itself is procedural and does not indicate noncompliance.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for GILD disclose?

The Form 144 discloses a proposed sale of 28,000 Gilead common shares with an aggregate market value of $3,318,924.65 to be executed through Morgan Stanley Smith Barney.

Who is the seller and which broker is handling the sale?

The filing lists sales by Johanna Mercier and the proposed 28,000-share sale is to be handled by Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York.

What recent equity acquisitions by the filer are disclosed?

Acquisitions disclosed include a 25,000-share stock option exercise (08/15/2025), 2,394 performance shares (01/31/2024), and 606 restricted shares (12/10/2023).

Does the filing list prior sales in the past three months?

Yes. The form lists multiple prior sales by Johanna Mercier with dates, amounts and gross proceeds, including sales on 05/22/2025, 06/16/2025, and 07/15/2025.

How many Gilead shares are outstanding according to the filing?

The filing states there are 1,240,806,916 shares outstanding.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

155.92B
1.24B
0.1%
90.75%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY